The report says that the Contract Research and Manufacturing Service (CRAMS) is becoming one of the most promising opportunities for the Indian pharma industry and India remains one of the most preferred outsourcing destinations.

Contract Manufacturing — The global manufacturing outsourcing opportunity is estimated at $20 billion and is expected to reach $31 billion by 2010.

Contract Research — The global contract research opportunity was pegged at $14 billion in 2006 and is expected to reach $24 billion by 2010.

Clinical Research — At present, a majority of clinical trials conducted in India are for Phase II and Phase III. The government is in the process of considering the recommendation of the Drug Technical Advisory Board (DTAB) to allow Phase I clinical trials for the drugs discovered abroad. If this happens, then it will enable the Indian CRAMS industry to provide a wide range of drug discovery services.

Government support — on the regulatory front, the government is also trying to promote the growth of this industry by providing a tax exemption on all services carried out by the contract research and clinical trials industry. In the product patent regime, many Indian pharma companies have embarked on R&D activities to achieve a sustainable long term advantage.

Various joint ventures have been formed between Indian and multinational pharma players to strengthen manufacturing capabilities, technology sharing and leveraging on the partner’s experience in product filings, regulatory compliance and the like.

Generics continue to remain the mainstay of the industry. Globally, the generics industry is expected to grow at a CAGR of 11 per cent between 2006 and 2010 and touch $94 billion by 2010. India has a 10 per cent share in this market. (http://www.hindu.com/biz/2007/11/05/stories/2007110550011700.htm)

At TASK we have extensive knowledge and experience of working with the leading pharmaceutical companies. Therefore, we have in depth understanding of the industry and can very well measure the requirements of the client companies. Pharma Team based centrally at the Corporate Office and managing business across India. Health Care grew National, focusing on Clinical Research, Core Pharma and Biotechnology…A Paradigm shift & growth the previous financial year.